Skip to main content
    I

    IRIDEX Corporation (IRIX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.69
    -0.00 (-0.32%)

    Market Cap: $12.12M

    Last updated: Nov 17, 2026 at 10:43 AM ET

    IRIDEX Corporation (IRIX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    IRIDEX (IRIX) trades at 0.2x sales and 3.3x book value. Its P/S of 0.2x is below its 5-year median of 0.6x. Its forward P/E is 769.2x.

    Current Multiples

    Its enterprise value is 108.8x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E769.2x
    Price to sales0.2x
    Price to book3.3x
    EV/EBITDA108.8x
    PEGN/A
    FCF yield-16.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 75.0% below 0.8x and its P/B is 6.5% above 3.1x.

    MultipleCurrent5-year median10-year median
    P/S0.2x0.6x0.8x
    P/B3.3x3.7x3.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.4x in 2025 to 3.1x in 2016. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$1.140.4x4.0x
    2024$1.680.6x13.3x
    2023$2.810.9x4.8x
    2022$2.010.6x1.9x
    2021$6.111.8x4.2x
    2020$2.511.0x2.0x
    2019$2.230.7x1.4x
    2018$4.701.3x2.1x
    2017$7.622.1x2.9x
    2016$14.063.1x3.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRIX

    What is IRIX's forward P/E ratio?

    IRIDEX has a forward P/E ratio of 769.2x.

    Is IRIX stock overvalued?

    GNG's valuation label for IRIX is Undervalued.

    What is IRIX's price to sales ratio?

    IRIDEX has a price to sales ratio of 0.2x.